Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies

NCT01663766 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01663766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01663766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2013
Completion date
March 31, 2015
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid or lymphoblastic leukemia (aml or all), chronic lymphocytic leukemia or small lymphocytic leukemia (cll or sll), chronic myelogenous leukemia (cml), gvhd (acute or chronic), multiple myeloma (mm), myelodysplastic syndrome, non-hodgekin lymphoma (nhl-both follicular & diffuse large cell)